Indian Pharmaceutical Companies and Biosimilar Keytruda
Indian pharmaceutical companies are preparing to launch biosimilar versions of Merck’s cancer immunotherapy drug, Keytruda, due to regulatory changes and the drug's impending patent expiration in key markets by 2028-29.
Keytruda: An Overview
- Global Sales: Expected to reach $31.7 billion by 2025.
- Uses: Treats multiple cancers including lung, head and neck, melanoma, urothelial, and gastrointestinal cancers.
- Cost Barrier: High cost limits access for most Indian patients, with treatment costing ₹20-30 lakh.
Biosimilar Market Potential
- Price Reduction: Biosimilar competition could lower prices by 50-80%, enhancing patient access.
- Key Players: Biocon, Zydus Lifesciences, Dr. Reddy’s Laboratories, Intas Pharmaceuticals, and Sun Pharma are preparing their strategies.
- Market Size: Estimated domestic market around ₹1,500 crore.
- Investment: Development requires ₹100-150 crore, limiting participation to established companies.
Regulatory and Market Dynamics
- Regulatory Changes: Phase-III confirmatory efficacy studies no longer mandatory, reducing development costs.
- Global Competition: Companies like Formycon, Samsung Bioepis, and Amgen are advancing development programs.
- Domestic Impact: Enhanced affordability could significantly increase patient access to immunotherapy.
Industry Insights and Future Outlook
- Doctor Insights: Affordability is the primary barrier; reduced prices could benefit more patients.
- Potential Patient Base: With over 1.5 million new cancer cases annually in India, biosimilars could help many eligible patients.
- Global Strategy: Indian companies aim to leverage manufacturing scale and cost advantages for global exports.
The launch of biosimilar Keytruda presents a significant opportunity for Indian pharmaceutical companies to expand patient access to cancer treatment both domestically and internationally, driven by reduced costs and regulatory changes.
